Top Stock Movers Oct 15, 2026: Why ESLA, XLAB, WETO Surged

ESLA — Estrella Immunopharma, Inc. (+69.6%)

Estrella Immunopharma closed up 69.6% at $0.54 on 120,372,308 shares. That is roughly 17 times its 20-day average of about 7.1 million. Market cap is only $13.9M, so this is a micro-cap.

Why is ESLA up? The most likely candidate is Estrella's press release that Intermountain Health LDS Hospital in Salt Lake City was activated as the fifth clinical site for its Phase I/II STARLIGHT-1 trial in B-cell non-Hodgkin's lymphoma. It is an operational update, not a financing, deal or analyst action, and nothing links it to the size of the move. One outlet, Chartmill, put the gain at about 27% to $0.41 in its report, so the exact size of the move is unclear. Sources also disagree on whether the release was dated October 14 or 15.

The technical picture is weak despite the spike. The stock sits 82.3% below its 52-week high, with a bearish moving-average stack, an RS rating of 9 and a trend-template score of 1. RSI is 56 and ADX is 50. StockSetups gives it a conviction score of 24/100 (grade D) and no actionable lane.

Squeeze conditions are modest. The squeeze score is 31/100, with free float at 27.1% (the share of stock that actually trades), short interest of 117,132 shares and 3.4 days to cover. Short-volume was 58% of the day's volume. The largest disclosed stake is 5.0%.

XLAB — Exascale Labs Holdings Inc. (+49.7%)

Exascale Labs closed up 49.7% at $1.36 on 7,469,028 shares, about 16 times its 20-day average of 453,023. It is a Technology name.

Why is XLAB up? No news, filing or announcement explains the move. The most recent filings are from late September: an 8-K on management, a 10-K annual report, an 8-K/A tied to M&A and an earnings 8-K, all tagged neutral. With no catalyst, the move looks momentum- and technically driven.

The chart shows a bullish engulfing candle, where a green candle fully covers the prior red one. That is often read as buyers taking control. Context matters, though: the stock is still 73.5% below its 52-wk high, RSI is 30 and ADX is 48. The conviction score is 100/100 (grade A+), although the technical rank is only 23.

Free float is 100%. The squeeze score is 45/100, with short interest of 518,598 shares and 1.0 days to cover. A short-sale restriction (SSR) is active, which limits when new short sales can occur. Thin trading history and a very low reported market cap make this a hazardous name.

WETO — Wetour Robotics Ltd (+45.7%)

Wetour Robotics closed up 45.7% at $1.21 on 68,459,306 shares, versus a 20-day average of about 8.9 million. Market cap is $69.0M. It gapped up 60.7% at the open, so much of the day's gain came before trading began. A gap is a jump between the prior close and the next open.

Why is WETO up? The most likely catalyst is Wetour's October 15 announcement that it paused sales under its at-the-market (ATM) share offering. In an ATM, a company sells new shares gradually into the market. The company said it paused while it evaluates market conditions and capital requirements, and will not start new ATM sales during the pause. The sources don't say the pause caused the rally, so that link is an inference from timing. No other company-specific news was found. Its two most recent filings, from September and October, were routine foreign-issuer 6-Ks.

Technically, the picture is poor: the stock is 99.0% below its 52-week high, with a bearish moving-average stack, RS rating of 1 and trend-template score of 1. RSI is 38 and ADX is 4, so there was no established trend. Conviction is 24/100 (grade D).

Free float is 25.9%, which is low. Still, the squeeze score is just 12/100, with 35,047 shares short and 0.0 days to cover. Short-volume was 57%. This does not look like a squeeze.

DRMA — Dermata Therapeutics, Inc. (+34.3%)

Dermata closed up 34.3% at $0.89 on 94,299,006 shares, about 20 times its 20-day average of 4.75 million. Market cap is just $2.5M.

Why is DRMA up? Dermata reported positive topline results from a cosmetic study of its Tome Foundational Treatment, a once-weekly skin renewal product. The open-label study enrolled 31 participants, and over 71% were graded as having overall skin improvement after a single treatment. The study was small and uncontrolled, and nothing else is reported behind the move. A shelf registration (S-3) was filed October 9; a shelf lets a company sell new shares later, which can dilute holders.

The chart printed an inverted hammer, a candle with a long upper wick that can signal selling into strength. The stock gapped up 18.1%. It remains 79.4% below its 52-week high, with a bearish moving-average stack, RSI of 39, ADX of 16, RS rating of 5 and conviction of 24/100 (grade D).

Squeeze setup is weak: score 17/100, free float 76.7%, short interest 167,251 shares, 1.2 days to cover and short-volume of 22%.

The bottom line

Today's biggest gainers are tiny, volatile stocks, and several moved without a clear reason. Spikes like these often give back much of the gain, and nothing here implies further upside. Even a perfect-looking pattern or squeeze setup can fail, so size positions small, set a stop, and do your own research. This is educational content, not financial advice.

StockSetups scans the full US universe after every close and every premarket morning for patterns, squeeze setups and unusual volume. Earlier recaps: Top Stock Movers Oct 14 and Premarket Movers Oct 15. A trading journal helps track what you learn.